GlassScriptPhysician profile
Jesse Romeu Velez
NPI 1215918420
$15,672.98
in general payments reported to CMS, 2019-2025
45 companies · $2,885 in 2025
The $2,885 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,787 · 2020: $1,837 · 2021: $2,048 · 2022: $1,664 · 2023: $2,238 · 2024: $2,214 · 2025: $2,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,736 · Consulting Fee: $400 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,736.32 |
| Consulting Fee | $400.00 |
| Education | $201.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,459.97 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,475.22 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Actelion Pharmaceuticals US, INC. | $1,955.29 | 2019-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,236.51 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $857.57 | 2019-2025 | Belsomra, Capvaxive, Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $818.42 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $681.91 | 2020-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $427.95 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $373.94 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $281.59 | 2022-2025 | |
| Pulmonx Corporation | $272.95 | 2022-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Insmed, INC. | $262.54 | 2020-2025 | Arikayce, Brinsupri |
| Amgen INC. | $260.08 | 2019-2025 | Tezspire |
| Mylan Specialty L.P. | $250.32 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $212.07 | 2020-2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Romeu Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.